2538 Response to cabazitaxel in patients with metastatic castrationresistant prostate cancer (mCRPC) poorly responding to docetaxel. (September 2015) - Angelergues, A.; Bellmunt, J.; Efstathiou, E.; Gonzalez, I.; Gyftaki, R.; Delanoy, N.; Ozguroglu, M.; Flechon, A.; Guillot, A.; Le Moulec, S.; Castellano, D.; Esteban, E.; et al.